Revvity (NYSE:RVTY) Upgraded by Zacks Research to “Hold” Rating

Zacks Research upgraded shares of Revvity (NYSE:RVTY) from a strong sell rating to a hold rating in a research note published on Tuesday morning,Zacks.com reports.

RVTY has been the subject of a number of other reports. Stifel Nicolaus reduced their price objective on shares of Revvity from $110.00 to $100.00 and set a “hold” rating for the company in a research note on Wednesday, May 6th. Weiss Ratings raised shares of Revvity from a “sell (d+)” rating to a “hold (c-)” rating in a research note on Thursday, July 30th. Robert W. Baird set a $117.00 price target on Revvity in a research note on Wednesday, May 6th. Barclays lifted their price objective on Revvity from $95.00 to $105.00 and gave the company an “equal weight” rating in a report on Thursday, May 7th. Finally, The Goldman Sachs Group dropped their target price on shares of Revvity from $110.00 to $95.00 and set a “neutral” rating on the stock in a report on Tuesday, April 14th. Three equities research analysts have rated the stock with a Buy rating and twelve have issued a Hold rating to the stock. Based on data from MarketBeat.com, the stock has a consensus rating of “Hold” and a consensus target price of $108.36.

Revvity Stock Up 3.4%

RVTY stock opened at $115.19 on Tuesday. The business has a 50 day moving average of $107.53 and a 200 day moving average of $99.91. The company has a quick ratio of 1.41, a current ratio of 1.80 and a debt-to-equity ratio of 0.36. The firm has a market cap of $12.85 billion, a PE ratio of 54.85, a price-to-earnings-growth ratio of 2.15 and a beta of 1.07. Revvity has a twelve month low of $81.22 and a twelve month high of $118.30.

Revvity (NYSE:RVTY) last posted its earnings results on Tuesday, August 4th. The company reported $1.41 EPS for the quarter, topping analysts’ consensus estimates of $1.21 by $0.20. The business had revenue of $711.00 million during the quarter, compared to analyst estimates of $702.96 million. Revvity had a return on equity of 8.34% and a net margin of 8.16%.The company’s quarterly revenue was down 1.3% compared to the same quarter last year. During the same quarter last year, the company earned $1.18 EPS. Revvity has set its FY 2026 guidance at 5.300-5.400 EPS. On average, research analysts forecast that Revvity will post 5.35 EPS for the current fiscal year.

Revvity Announces Dividend

The firm also recently announced a quarterly dividend, which will be paid on Friday, November 13th. Investors of record on Friday, October 23rd will be paid a dividend of $0.07 per share. This represents a $0.28 annualized dividend and a yield of 0.2%. The ex-dividend date is Friday, October 23rd. Revvity’s payout ratio is 13.40%.

Institutional Inflows and Outflows

Several institutional investors have recently modified their holdings of RVTY. Ascentis Independent Advisors acquired a new stake in shares of Revvity in the first quarter valued at about $29,000. CYBER HORNET ETFs LLC purchased a new position in Revvity during the second quarter worth about $32,000. MUFG Securities EMEA plc acquired a new stake in shares of Revvity during the 2nd quarter worth approximately $34,000. SJS Investment Consulting Inc. lifted its stake in shares of Revvity by 5,210.0% in the 1st quarter. SJS Investment Consulting Inc. now owns 531 shares of the company’s stock valued at $47,000 after purchasing an additional 521 shares during the last quarter. Finally, Headlands Technologies LLC purchased a new stake in Revvity in the 2nd quarter valued at about $49,000. 86.65% of the stock is currently owned by hedge funds and other institutional investors.

Revvity Company Profile

Revvity, Inc is a global provider of technology-enabled solutions for the life sciences, diagnostics and applied markets. The company develops and supplies a range of products and services, including reagents and consumables, laboratory instruments, workflow automation, software analytics and technical support. Its portfolio supports applications in drug discovery, genomics, cell biology research, environmental and food safety testing, industrial quality control and clinical diagnostics.

Tracing its heritage to Perkin-Elmer, founded in 1937, Revvity began trading on the New York Stock Exchange under the ticker symbol RVTY in January 2024 following a corporate rebranding.